Key facts
- Shenandoah Therapeutics’s last known valuation is $37.0M (Mar 2025).
- It has raised $21.5M across 1 recorded rounds; the latest was Early Stage VC ($21.5M) in May 2025.
- Notable investors include Samsara BioCapital, Honghui Capital, First Spark Ventures, Time BioVentures, YK Bioventures.
- Shenandoah Therapeutics has filed 1 Form D with the SEC, most recently May 2025 ($21.5M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Shenandoah Therapeutics
Funding rounds
1 roundsAbout Shenandoah Therapeutics
Developer of an oncology technology platform designed for cancer treatment. The company's platform utilizes a combination of proteins, including transcriptional chemical inducers of proximity, which trigger cancer cells to self-destruct, enabling medical professionals to offer new therapeutic options for cancer patients.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2022
- Employees
- 5
- Website
- shenandoah-tx.com/
- Ownership
- Privately Held (backing)
Shenandoah Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shenandoah Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shenandoah Therapeutics in its N-PORT filings yet. We sweep new filings monthly.